Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF – Get Free Report) was the recipient of a large drop in short interest in January. As of January 15th, there was short interest totaling 70,538 shares, a drop of 23.0% from the December 31st total of 91,573 shares. Approximately 0.4% of the shares of the stock are short sold. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days. Approximately 0.4% of the shares of the stock are short sold.
Newron Pharmaceuticals Price Performance
NWPHF opened at $9.36 on Tuesday. The stock’s fifty day moving average is $9.36 and its 200-day moving average is $9.36. Newron Pharmaceuticals has a one year low of $9.10 and a one year high of $12.00.
About Newron Pharmaceuticals
Newron Pharmaceuticals SpA is a clinical-stage biopharmaceutical company headquartered in Bresso, Italy, dedicated to developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts focus on small-molecule compounds designed to address unmet medical needs in neurology and psychiatry.
Newron’s lead product, safinamide, is marketed under the brand name Xadago as an adjunctive therapy for patients with mid- to late-stage Parkinson’s disease.
Featured Stories
- Five stocks we like better than Newron Pharmaceuticals
- The day the gold market broke
- Forget AI, This Will Be the Next Big Tech Breakthrough
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- Gold’s getting scarce.
- ALERT: Drop these 5 stocks before the market opens tomorrow!
Receive News & Ratings for Newron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Newron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
